HOOKIPA Pharma Q4 2023 Earnings Report

HOOKIPA Pharma EPS Results

• Actual EPS: -$1.10
• Consensus EPS: -$2.00
• Beat/Miss: Beat by +$0.90
• One Year Ago EPS: N/A

HOOKIPA Pharma Revenue Results

• Actual Revenue: $7.41 million
• Expected Revenue: $3.60 million
• Beat/Miss: Beat by +$3.81 million
• YoY Revenue Growth: N/A

HOOKIPA Pharma Announcement Details

• Quarter: Q4 2023
• Date: 3/22/2024
• Time: N/A
• Conference Call Date: Friday, March 22, 2024
• Conference Call Time: 7:00AM ET

HOOKIPA Pharma (NASDAQ:HOOK) is a clinical-stage biotechnology company focused on the development of virus-based immunotherapies and vaccines. The company operates two complementary platform technologies—an engineered Modified Vaccinia Ankara (MVA) vector and an arenavirus vector system—designed to stimulate both humoral and cellular immune responses. By combining these platforms, HOOKIPA aims to address infectious diseases and drive novel immuno-oncology treatments.

In the infectious disease arena, HOOKIPA’s pipeline includes prophylactic vaccine candidates targeting pathogens such as cytomegalovirus (CMV) in transplant settings and other viral threats. The arenavirus-based platform is leveraged to induce strong T-cell responses against persistent viruses, while the MVA vector is optimized for broader antibody and T-cell activation. Preclinical and early clinical data have underscored the potential of these approaches to provide durable immunity with a favorable safety profile.

Beyond infectious disease, HOOKIPA is advancing immuno-oncology programs that employ its vector systems to generate anti-tumor immune responses. These candidates are engineered to present tumor-associated antigens, aiming to recruit and expand cytotoxic T cells within the tumor microenvironment. This dual focus on both prophylactic and therapeutic indications reflects the company’s strategy to harness its platform versatility across multiple disease areas.

Founded in 2016, HOOKIPA Pharma is headquartered in Vienna, Austria, with a U.S. subsidiary based in New York. The company’s leadership team comprises experienced executives and scientific founders who have previously held senior roles in biopharmaceutical research and development. HOOKIPA continues to collaborate with academic institutions and industry partners to advance its clinical pipeline and expand the reach of its novel immunotherapy platforms.